The yawning elicited by α-melanocyte-stimulating hormone involves serotonergic-dopaminergic-cholinergic neuron link in rats

  • Katsushi Yamada
  • Tatsuo Furukawa
Article

Summary

A behavioral study was performed in an attempt to understand the neuronal mechanisms involved in yawning and ‘Wet-Dog’ body shaking in rats.

  1. 1.

    Physostigmine (0.2 mg/kg, i. p.) and pilocarpine (4 mg/kg, i. p.) induced yawning. The physostigmine-induced yawning was markedly inhibited by high doses (4, 8 mg/kg, i. p.) of apomorphine which preferentially stimulate postsynaptic dopamine receptors but was not inhibited by methysergide, whereas the pilocarpine-induced yawning was unaffected by either apomorphine or methysergide.

     
  2. 2.

    Intraperitoneal injections of low doses (5 mg/kg, i. p.) of piribedil, which preferentially activate presynaptic dopamine autoreceptors, also elicited yawning. At a high dose of 80 mg/kg, piribedil produces stereotypy which has been thought to be mediated by stimulation of postsynaptic dopamine receptors. The yawning and stereotypy did not occur simultaneously in the rat. The piribedil-induced yawning was markedly inhibited after treatment with fluphenazine, scopolamine or methysergide.

     
  3. 3.

    Intraventricular injection of α-melanocyte-stimulating hormone (α-MSH, 10 μg/rat) elicited not only yawningstretching syndrome but also ‘Wet-Dog’ body shaking. Yawning synchronized with stretching in almost all cases. The α-MSH-induced yawning-stretching syndrome was blocked by scopolamine, apomorphine (8 mg/kg×3, i. p.), fluphenazine or methysergide, while body shaking was inhibited by methysergide, apomorphine or fluphenazine but was not inhibited by scopolamine.

     
  4. 4.

    Body shaking was also produced by 5-hydroxytryptophan (150 mg/kg, s. c.) in combination with a peripheral decarboxylase inhibitor, Ro 4-4602 (50 mg/kg, i. p.), accompanied rarely by yawning and stretching.

     
  5. 5.

    The present results indicate that a reciprocal balance of serotonergic activation-dopaminergic inhibition-cholinergic activation is involved in the yawning, and that α-MSH also induces body shaking by activating in part the central serotonergic neuron system.

     

Key words

Yawning ‘Wet-Dog’ body shaking α-Melanocyte-stimulating hormone Dopaminergic agonists Cholinergic agonists 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baldwin DM, Haun CK, Sawyer CH (1974) Effects of intraventricular infusions of ACTH1–24 and ACTH4–10 on LH release, ovulation and behavior in the rabbit. Brain Res 80:291–301Google Scholar
  2. Bedard P, Pycock CJ (1977) ‘Wet-Dog’ shake behavior in the rat: A possible quantitative model of central 5-hydroxytryptamine activity. Neuropharmacology 16:663–670Google Scholar
  3. Biscoe TJ, Straughan DW (1966) Microelectrophoretic studies of neurones in the cat hippocampus. J Physiol (Lond) 183:341–359Google Scholar
  4. Carlsson A (1975) Receptor-mediated control of dopamine metabolism. In: Usdin E, Bunny WE (eds) Pre- and postsynaptic receptors. Marcel Dekker, New York, p 49Google Scholar
  5. Carter CJ, Pycock CJ (1978) A study of the sites of interaction between dopamine and 5-hydroxytryptamine for the production of fluphenazine-induced catalepsy. Naunyn-Schmiedeberg's Arch Pharmacol 304:135–139Google Scholar
  6. Choi RL, Roth RH (1978) Development of supersensitivity of apomorphine-induced increase in acetylcholine levels and stereotypy after chronic fluphenazine treatment. Neuropharmacology 17:59–64Google Scholar
  7. Cools A, Van Rossum JM (1976) Excitation-mediating and inhibition-mediating dopamine-receptors: A new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data. Psychopharmacologia 45:243–254Google Scholar
  8. Costall B, Naylor RJ (1973a) oN the mode of action of apomorphine. Eur J Pharmacol 21:350–361Google Scholar
  9. Costall B, Naylor RJ (1973b) The site and mode of action of ET-495 for the mediation of stereotyped behaviour in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 278:117–133Google Scholar
  10. Douglas WW (1975) Histamine and antihistamines; 5-hydroxytryptamine and antagonists. In: Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics. Macmillan, New York, p 590Google Scholar
  11. Ferrari W, Gessa GL, Vargiu L (1963) Behavioral effects induced by intracisternally injected ACTH and MSH. Ann NY Acad Sci 104:330–345Google Scholar
  12. Fozard JR, Palfreyman MG (1979) Metoclopramide antagonism of 5-hydroxytryptophan-induced ‘Wet-dog’ shake behavior in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 307:135–142Google Scholar
  13. Furukawa T, Yamada K (1980) The α-naphthoxyacetic acid-elicited retching involves dopaminergic inhibition in mice. Pharmacol Biochem Behav 12:735–738Google Scholar
  14. Fuxe K (1965) The distribution of monoamine terminals in the central nervous system. Acta Physiol Scand 64 Suppl 247:41–85Google Scholar
  15. Gessa GL, Vargiu L, Ferrari W (1966) Stretching and yawnings induced by adrenocorticotrophic hormone. Nature 211:426–427Google Scholar
  16. Gispen WH, Wiegant VM, Greven HM, De Wied D (1975) The induction of excessive grooming in the rat by intraventricular application of peptides derived from ACTH: Structure-activity studies. Life Sci 17:645–652Google Scholar
  17. Groves PM, Wilson CJ, Young SJ, Rebec GV (1975) Self-inhibition by dopaminergic neurons: An alternative to the “neuronal feed back loop” hypothesis for the mode of action of certain psychotropic drugs. Science 190:522–529Google Scholar
  18. Himmelsbach CK (1939) Studies of certain addiction characteristics of (a) dihydromorphine (“paramorphan”), (b) dihydrodesoxymorphine-D (“desomorphine”), (c) dihydrodesoxycodeine-D (“desocodeine”), and (d) methyldihydromorphinone (“metopon”). J Pharmacol Exp Ther 67:239–249Google Scholar
  19. Innes IR, Nickerson M (1975) Atropine, scopolamine, and related antimuscarinic drugs. In: Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics. Macmillan, New York, p 514Google Scholar
  20. Kataoka A, Kóriyama T, Arimura K, Enatsu M, Igata A, Tokito S (1980) Adrenoleukodystrophy and yawning. Autonomic Nervous System 17:24–25Google Scholar
  21. Ladinsky H, Consolo S, Garattini S (1974) Increase in striatal acetylcholine levels in vivo by piribedil, a new dopamine receptor stimulant. Life Sci 14:1251–1260Google Scholar
  22. Lal H, Numan R (1976) Blockade of morphine-withdrawal body shakes by haloperidol. Life Sci 18:163–168Google Scholar
  23. Nicolaou NM, Garcia-Munoz M, Arbuthnott GW, Eccleston D (1979) Interactions between serotonergic and dopaminergic systems in rat brain demonstrated by small unilateral lesions of the raphe nuclei. Eur J Pharmacol 57:295–305Google Scholar
  24. Nowycky MC, Roth RH (1977) Presynaptic dopamine receptors: Development of supersensitivity following treatment with fluphenazine decanoate. Naunyn-Schmiedeberg's Arch Pharmacol 300:247–254Google Scholar
  25. Pellegrino LJ, Pellegrino AS, Cushmann AJ (1979) A sterotaxic atlas of the rat brain. Plenum Press, New YorkGoogle Scholar
  26. Prange AJ Jr, Wilson IC, Lara PP, Alltop LB, Breese GR (1972) Effects of thyrotropin-releasing hormone in depression. Lancet II:999–1002Google Scholar
  27. Rees HD, Dunn AJ, Iuvone PM (1976) Behavioral and biochemical responses of mice to the intraventricular administration of ACTH analogs and lysine vasopressin. Life Sci 18:1333–1340Google Scholar
  28. Robinson S, Cheney DL, Moroni F, Costa E (1978) Acetylcholine turnover in specific brain areas of rats injected with various antidepressants. In: Garrattini S (ed) Depressive disorders. Schattauer Verlag, Berlin, p 129Google Scholar
  29. Robinson SE, Malthe-Sørenssen D, Wood PL, Comissiong J (1979) Dopaminergic control of the septal-hippocampal cholinergic pathway. J Pharmacol Exp Ther 208:476–479Google Scholar
  30. Rommelspacher H, Kuhar MJ (1974) Effects of electrical stimulation on acetylcholine levels in central cholinergic nerve terminals. Brain Res 81:243–251Google Scholar
  31. Seevers MH (1936) Opiate addiction in the monkey. I. Methods of study. J Pharmacol Exp Ther 56:147–156Google Scholar
  32. Siegel S (1956) Nonparametric statistics for the behavioral sciences. McGraw-Hill, TokyoGoogle Scholar
  33. Storm-Mathisen J (1970) Quantitative histochemistry of acetylcholinesterase in rat hippocampal region correlated to histochemical staining. J Neurochem 17:739–750Google Scholar
  34. Strömbom U (1976) Catecholamine receptor agonists. Naunyn-Schmiedeberg's Arch Pharmacol 292:167–176Google Scholar
  35. Urbá-Holmgren R, Gonzalez RM, Holmgren B (1977) Is yawing a cholinergic response? Nature 267:261–262Google Scholar
  36. Walters J, Roth R (1976) Dopaminergic neurons: An in vivo system for measuring drug interactions with presynaptic receptors. Naunyn-Schmiedeberg's Arch Pharmacol 296:5–14Google Scholar
  37. Wei E, Sigel S, Loh H, Way EL (1975) Thyrotropin-releasing hormone and shaking behavior in rat. Nature 253:739–740Google Scholar
  38. Wood PL, Cheney DL, Costa E (1979) Modulation of the turnover rate of hippocampal acetylcholine by neuropeptides: Possible site of action of α-melanocyte-stimulating hormone, adrenocorticotrophic hormone and somatostatin. J Pharmacol Exp Ther 209:97–103Google Scholar
  39. Yamada K, Furukawa T (1980a) Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning. Psychopharmacology 67:39–43Google Scholar
  40. Yamada K, Furukawa T (1980b) Dopaminergic inhibition involved in the α-naphthoxyacetic acid-induced jumping behavior in mice. Eur J Pharmacol 63:321–325Google Scholar
  41. Yamada K, Furukawa T (1980c) Behavior of rats and mice administered active metabolites of fluphenazine, 7-hydroxy-fluphenazine and fluphenazine-sulfoxide. Arch Int Pharmacodyn Ther (in press)Google Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • Katsushi Yamada
    • 1
  • Tatsuo Furukawa
    • 1
  1. 1.Department of Pharmacology, School of MedicineFukuoka UniversityFukuokaJapan

Personalised recommendations